Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 29
- Registration Number
- NCT00574171
- Locations
- 🇺🇸
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 163
- Registration Number
- NCT00558103
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
- Conditions
- Interventions
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 455
- Registration Number
- NCT00553358
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom
Lapatinib and Trastuzumab With or Without Endocrine Therapy
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Baylor Breast Care Center
- Target Recruit Count
- 65
- Registration Number
- NCT00548184
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bunting-Blaustein Cancer Research, Baltimore, Maryland, United States
🇺🇸UAB Cancer Center, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Bevacizumab in Multiple Phase I Combinations
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 343
- Registration Number
- NCT00543504
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00536809
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00528281
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
- Conditions
- Interventions
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT00524303
- Locations
- 🇺🇸
GSK Investigational Site, Yakima, Washington, United States
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00516672
- Locations
- 🇯🇵
GSK Investigational Site, Saitama, Japan
Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 33
- Registration Number
- NCT00513058
- Locations
- 🇫🇷
Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
🇫🇷Centre Oscar Lambret, Lille, France
🇫🇷Institut Curie Hopital, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.